Trial Profile
Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 11 May 2021
Price :
$35
*
At a glance
- Drugs Pitavastatin (Primary)
- Indications Dyslipidaemias; Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Sponsors Kowa Research Institute
- 06 May 2021 Status changed from discontinued to withdrawn prior to enrolment.
- 07 Jun 2016 Status changed from withdrawn prior to enrolment to discontinued.
- 06 Jun 2016 Status changed from recruiting to withdrawn prior to enrolment.